Advancing RSV Research: Expanding Therapeutic Options with Recombinant Antibodies and Antigens with Live Q&A

Human respiratory syncytial virus (RSV) remains a significant public health concern, particularly for vulnerable populations such as infants, young children, and immunocompromised individuals. In this webinar we focus on the crucial role of RSV antigens and antibodies in research, and the development of diagnostics, therapeutics, and vaccines against RSV. We will provide a comprehensive overview of RSV, highlighting its epidemiology, clinical manifestations, and associated complications. Through this talk, we aim to showcase the power of recombinant antigens and antibodies in enhancing RSV detection, characterization, and understanding of viral pathogenesis.

Learning Objectives:

1. Outline the human respiratory syncytial virus (RSV) and its impact on public health.

2. Identify RSV’s major antigens such as the fusion (F) protein, attachment (G) protein, and matrix (M) protein and their functions.

3. Discuss biomedical research on RSV and the crucial role of recombinant antigens and antibodies.

4. Discuss RSV vaccine development: challenges and future directions.